Crinetics Pharmaceuticals (CRNX) Cash from Operations (2017 - 2026)

Crinetics Pharmaceuticals' Cash from Operations history runs 10 years deep, the most recent figure standing at 124703000.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 40.98% year-over-year to 124703000.0; the TTM figure through Mar 2026 stood at 414173000.0 (down 55.83% YoY), while the FY2025 annual figure was 377922000.0, down 64.18% from the prior year.
• Cash from Operations for Q1 2026 stood at 124703000.0, down from 92901000.0 in the prior quarter.
• The five-year high for Cash from Operations was 13543000.0 in Q1 2022, with the low at 124703000.0 in Q1 2026.
• The 5-year median for Cash from Operations is 47644000.0 (2024), against an average of 59801294.12.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations jumped 32.51% in 2022, then plunged 200.66% in 2023.
• Crinetics Pharmaceuticals' Cash from Operations stood at 35207000.0 in 2022, then declined by 15.9% to 40806000.0 in 2023, then sank by 63.88% to 66871000.0 in 2024, then plunged by 38.93% to 92901000.0 in 2025, then plunged by 34.23% to 124703000.0 in 2026.
• Business Quant data shows CRNX's Cash from Operations at 124703000.0 in Q1 2026, 92901000.0 in Q4 2025, and 110718000.0 in Q3 2025.